Top Story

Lenalidomide–dexamethasone extended PFS, OS in transplant-ineligible multiple myeloma

September 22, 2014

Continuous lenalidomide plus low-dose dexamethasone significantly extended PFS compared with melphalan, prednisone and thalidomide in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, according to phase 3 study results.

Results of an interim analysis showed the combination of lenalidomide (Revlimid, Celgene) and dexamethasone also demonstrated a trend toward improved OS.

figure Meeting News CoverageVideo

Contralateral mastectomy did not provide significant survival benefit in young women

September 21, 2014
SAN FRANCISCO — Antoine Bouchard-Fortier, MD, a second-year surgical oncology fellow at the University of Calgary Tom Baker Cancer Center, offers insights into…
figure Meeting News CoverageVideo

Triptorelin, chemotherapy combination preserved long-term ovarian function

September 20, 2014
SAN FRANCISCO — Matteo Lambertini, MD, of the department of medical oncology at U.O. Oncologia Medica 2 in Italy, discusses long-term results of the PROMISE-GIM6…
figure Meeting News CoverageVideo

Tumor subtype provided prognostic factor for survival after WBRT for metastatic breast cancer

September 19, 2014
SAN FRANCISCO — Vipin Das Villgran, MD, medical resident at University of Pittsburgh Medical Center, discusses study results which found that tumor subtype…
More News Headlines »
Pharmacology Consult Publication Exclusive
figure

Emerging data will determine role of ramucirumab in treatment of advanced gastric cancer

HemOnc Today, July 25, 2014
Van Nguyen, PharmD, BCOP
Despite current therapies, gastric cancer remains the second leading cause of cancer-related mortality worldwide…
More »
Meeting News Coverage Video
figure

Contralateral mastectomy did not provide significant survival benefit in young women

September 21, 2014
SAN FRANCISCO — Antoine Bouchard-Fortier, MD, a second-year surgical oncology fellow at the University of…
More »